How Trump's trade tariffs could affect the cost of coffee in the US – visualized
The United States is the largest importer of coffee in the world, and its biggest supplier is Brazil. Earlier this month, US President Donald Trump threatened to impose 50% tariffs on Brazilian goods if President Luiz Inácio Lula da Silva continued a legal inquiry on former Brazilian leader Jair Bolsonaro.
Here's a look at the value of the coffee trade, US coffee-drinking habits and why your cup of coffee could be more expensive very soon, if Trump goes ahead with his latest tariff plan.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
Unlocking Oncology's Future: 3 Trending Cancer Biotech Stocks with ‘Strong Buy' Ratings
Cancer remains one of the most relentless challenges in modern medicine. In 2025, over 2 million new cancer cases are expected to be diagnosed in the United States. More than 618,000 people will die from the disease, which is equivalent to about 1,700 deaths each day. The scale of this health crisis is driving substantial investments and innovation in cancer research and treatment. As a result, the global oncology market is projected to reach $208.9 billion in revenue by 2025, with forecasts suggesting it could surpass $900 billion by 2034. This growth is fueled by increased cancer incidence, advances in precision and immunotherapy drugs, and billions of dollars in new partnerships and funding, such as Bristol-Myers Squibb's (BMY) recent $11 billion stake in next-generation cancer therapies. More News from Barchart Warren Buffett Warns Inflation Turns Business Into 'The Upside-Down World of Alice in Wonderland' But Weeds Out 'Bad Businesses' Why GOOGL Stock May Be the Market's Next Big Winner Alphabet Posts Lower Free Cash Flow and FCF Margins - Is GOOGL Stock Overvalued? Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. High-potential cancer specialists like Elicio Therapeutics (ELTX), Cellectis (CLLS), and Autolus Therapeutics (AUTL) are earning coveted 'Strong Buy' analyst ratings. Despite this recognition, each remains well below large-cap valuations, which leaves ample room for sharp upside if upcoming clinical and regulatory catalysts play out in their favor. Could one of these under-the-radar biotech firms deliver the next big breakthrough in cancer treatment — and major upside for investors? Let's dive into these three cancer biotech stocks now. Elicio Therapeutics Elicio Therapeutics (ELTX) is a clinical-stage biotech pioneering immunotherapies for solid tumors, with a market capitalization of $158 million. ELTX has posted a YTD gain of 92.7%, and is up 102.6% over the past 52 weeks. Its price-book ratio stands at an elevated 17.6x, well above the sector median of 2.47x. Elicio's lead asset, ELI-002 7P, is advancing through the pivotal Phase 2 AMPLIFY-7P trial targeting pancreatic ductal adenocarcinoma (PDAC), with a critical interim analysis focused on disease-free survival slated for Q3 2025. This interim analysis is a key milestone for the company, particularly for its potential impact on PDAC. Ahead of this readout, H.C. Wainwright analyst Robert Burns reiterated a 'Buy' rating on shares and maintained his $13 price target. Elicio reported Q1 2025 R&D expenses of $7.8 million, a slight increase from $7.6 million in Q1 2024, tied primarily to the ongoing Phase 2 AMPLIFY-7P trial. General and administrative expenses grew to $3 million, up from $2.7 million due to higher personnel costs. The Q1 2025 net loss narrowed to $11.2 million, compared to $11.8 million in the same quarter last year, with a net loss per share improving to $0.87 from $1.15. Notably, ELTX augmented its financial position in Q2 by securing a $10 million senior secured note, extending its operational runway into early 2026 and granting the company flexibility for near-term initiatives. Analyst sentiment skews highly bullish as the two surveyed analysts assign ELTX a 'Strong Buy' rating, with an average price target of $12.50. This places the upside potential at approximately 26% from current levels. Cellectis Cellectis (CLLS) is a clinical-stage biotech company specializing in gene-edited cell therapies with a market capitalization of approximately $140 million. The stock has gained 60% in the year to date, and shares are up 25.2% in the past 52 weeks. Cellectis has a price-sales ratio of 2.26x, below the sector median of 3.6x, and a price-book ratio of 0.96x, significantly under the sector median of 2.47x, suggesting potential undervaluation relative to its peers. CLLS reported solid results for Q1 2025, with consolidated revenues and other income rising to $12 million from $6.5 million a year prior. This increase mainly stems from $5.9 million recognized under the AstraZeneca Joint Research Collaboration Agreement (AZ JRCA). Its cash reserves stood at $246 million as of March 31, 2025, projected to sustain operations well into the second half of 2027, providing ample runway for ongoing development. Research and development expenses slightly decreased to $21.9 million compared to the previous year, reflecting efficient management despite continued investment in pipeline advancement and manufacturing capabilities in Paris and Raleigh. Strategically, Cellectis' partnership with AstraZeneca is a cornerstone of its growth story. AstraZeneca's $140 million investment enhances Cellectis' financial footing and grants AstraZeneca exclusive rights to 25 genetic targets, with options to develop up to 10 candidate products. So far this collaboration is advancing two CAR-T programs aimed at hematological malignancies and solid tumors. Analyst sentiment is unanimously bullish, with the five surveyed analysts assigning Cellectis a consensus 'Strong Buy' rating. The average price target of $5.60 implies compelling upside of approximately 91% from the current share price. Autolus Therapeutics Autolus Therapeutics (AUTL) develops advanced autologous CAR-T cell therapies for blood cancers, with a market capitalization of $670 million. The stock is up 8.7% year-to-date, but down 45% over the past 52 weeks. Its price-sales ratio of 69.4xx is markedly above the sector's 3.54x median, while its 1.89x price-book ratio remains below group averages of 2.47x. In Q1 2025, Autolus reported $9 million in net product revenue, driven largely by the commercial rollout of AUCATZYL (Obe-cel), its lead CAR-T therapy, across 39 fully activated U.S. centers. Patient access continues to grow, capturing coverage for roughly 90% of U.S. medical lives as payer uptake accelerates. Costs of sales totaled $18 million, including delivered but as-yet-unrecognized product tied to deferred revenue and royalty obligations, a natural part of early stage commercial launches. Research and development expenses dropped to $26.7 million from $30.7 million year-over-year, with much of that shift driven by the transition of manufacturing expenses to sales costs. Loss from operations widened to $65.2 million due to launch investments, and net loss reached $70.2 million or $0.26 per share. On the regulatory front, Autolus scored a critical win in July as AUCATZYL secured European approval for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. This unlocks a larger addressable market and enhances the company's global competitive position in engineered cell therapies. The analyst outlook remains unequivocally positive as the nine surveyed analysts rate AUTL a consensus 'Strong Buy,' with a mean target of $9.84, implying 285% upside potential from current levels. Conclusion With major catalysts ahead and strong analyst backing, the odds favor upward momentum as data readouts and commercial expansion play out. Given their positioning and partnerships, these three stocks could deliver outsized gains in the coming quarters, especially if results come in strong. On the date of publication, Ebube Jones did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Yahoo
5 minutes ago
- Yahoo
The New Big Fear In Retirement Planning Is 100% Legit — How To Tackle It
American confidence in retirement planning is at an all-time low, dropping from 83% in 2020 to only 70% in 2025, according to the Allianz Center for the Future of Retirement's '2025 Annual Retirement Study.' The research found that instead of looking forward to their golden years, Americans are more fearful than ever. Be Aware: Explore More: While numerous factors contribute to this fear-based mindset, the most prominent is the ability to save. Only around 55% of Americans are currently saving enough to support their retirement years, with only 48% of millennials, 59% of Gen Xers and 74% of boomers putting enough aside to live comfortably after retirement. But what additional factors play a role in the growing fear surrounding retirement planning, and what steps can you take to tackle them? Having a plan in place can help restore your confidence and make planning for retirement more successful. Factors Impacting Retirement Planning The ability to save enough money for retirement is Americans' biggest fear, but other factors directly impact the ability to do so. Here are a few. Increasing Healthcare Costs As healthcare costs continue to increase, they account for a larger portion of many Americans' retirement savings. Even with insurance, healthcare expenses can make it difficult to save and maintain those savings long-term. For You: Inflation As the dollar loses its value, retirement savings effectively shrink. Inflation's devastating impact on purchasing power means retirees must have a larger income to support their lifestyle in retirement. Stock Market Fluctuations Volatility in the stock market can wreak havoc on retirement portfolios, causing anxiety for the millions of Americans who rely on their investment income. Uncertainty surrounding the stability of these investments can make retirement planning even more challenging. Recession While the American economy isn't currently in a recession, a whopping 62% of Americans cite it as a large concern when planning for retirement. A global or national financial crisis could devastate many retirement portfolios, wiping out a lifetime of savings. How To Overcome Retirement Planning Fears Tackling the fear of having enough saved for retirement can seem overwhelming, but with common-sense solutions, you can help set yourself up for long-term financial success. Develop a Comprehensive Retirement Strategy Creating a comprehensive retirement strategy that outlines your financial goals, budget and ways to increase your savings can keep you on track and ready when the unexpected occurs. Consider Guaranteed Income Options Having a steady, guaranteed income can offer unmatched peace of mind during retirement. Options like annuities are great, especially when started early. Research Healthcare Options Researching your healthcare options, such as Medicaid plans, Health Savings Accounts and supplemental insurance, can help you offset large healthcare costs. Plan for Market Volatility Diversifying your assets can protect your savings during market fluctuations and help you maintain a steady income throughout your retirement. Creating a plan to grow and protect your savings will give you confidence as you plan for retirement. Whether you work with a financial advisor or tackle it yourself, having a sound financial strategy will help mitigate long-term risk for a financially secure retirement. More From GOBankingRates Mark Cuban Warns of 'Red Rural Recession' -- 4 States That Could Get Hit Hard 5 Cities You Need To Consider If You're Retiring in 2025 4 Housing Markets That Have Plummeted in Value Over the Past 5 Years This article originally appeared on The New Big Fear In Retirement Planning Is 100% Legit — How To Tackle It
Yahoo
5 minutes ago
- Yahoo
Trump eyes 'world tariff' of 15-20% for most countries
By Andrea Shalal TURNBERRY, Scotland (Reuters) -President Donald Trump said on Monday most trading partners that do not negotiate separate trade deals would soon face tariffs of 15% to 20% on their exports to the United States, well above the broad 10% tariff he imposed in April. Trump told reporters his administration will notify some 200 countries soon of their new "world tariff" rate. "I would say it'll be somewhere in the 15 to 20% range," Trump told reporters, sitting alongside British Prime Minister Keir Starmer at his luxury golf resort in Turnberry, Scotland. "Probably one of those two numbers." Trump, who has vowed to end decades of U.S. trade deficits by imposing tariffs on nearly all trading partners, has already announced higher rates of up to 50% on some countries, including Brazil, starting on Friday. The announcements have spurred feverish negotiations by a host of countries seeking lower tariff rates, including India, Pakistan, Canada, and Thailand, among others. The U.S. president on Sunday clinched a huge trade deal with the European Union that includes a 15% tariff on most EU goods, $600 billion of investments in the U.S. by European firms, and $750 billion in energy purchases over the next three years. That followed a $550-billion deal with Japan last week and smaller agreements with Britain, Indonesia, and Vietnam. Other talks are ongoing, including with India, but prospects have dimmed for many more agreements before Friday, Trump's deadline for deals before higher rates take effect. Trump has repeatedly said he favors straightforward tariff rates over complex negotiations. "We're going to be setting a tariff for essentially, the rest of the world," he said again on Monday. "And that's what they're going to pay if they want to do business in the United States. Because you can't sit down and make 200 deals." Canadian Prime Minister Mark Carney said on Monday trade talks with the U.S. were at an intense phase, conceding that his country was still hoping to walk away with a tariff rate below the 35% announced by Trump on some Canadian imports. Carney conceded this month that Canada - which sends 75% of its exports to the United States - would likely have to accept some tariffs. (Additional reporting by Andrew MacAskill in Turnberry, Andrea Shalal in Edinburgh and William James in LondonEditing by Rod Nickel) Sign in to access your portfolio
